Close Menu

NEW YORK – DiaSorin Molecular announced on Tuesday the US Food and Drug Administration has cleared the company's Simplexa Flu A/B and RSV Direct Gen II kit.

The test can be run alone or with the Simplexa COVID-19 Direct kit for the differential diagnosis of SARS-CoV-2, influenza A/B, and respiratory syncytial virus, the Cypress, California-based company said. The Simplexa COVID-19 Direct kit received Emergency Use Authorization from the FDA in March.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.